On June 2, 2026, Chime Biologics and Daewoong Pharmaceutical announced a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Sanofi and Regeneron’s DUPIXENT.
Chime Biologics is a global CDMO headquartered in China and with major development hubs in Basel, Shanghai, and Wuhan. Daewoong is a South Korean pharmaceutical developer with a broad pipeline spanning preclinical to NDA-stage therapeutics with targets ranging from autoimmune diseases and metabolic disorders to fibrosis and oncology. Through their partnership, the companies aim to leverage Chime Biologics’ AI-enabled development platform and bioprocess supply chain ecosystem to support development of Daewoong’s first global biosimilar product and strengthen Daewoong’s position in the global biosimilars market.
Dupilumab is a monoclonal antibody therapy that treats immunological diseases by blocking interleukin 4 and interleukin 13 receptor signaling-induced type 2 inflammation. DUPIXENT is approved for the treatment of asthma, atopic dermatitis (eczema), chronic obstructive pulmonary disease (COPD), and several other inflammatory diseases. In 2025, DUPIXENT generated approximately $17.8 billion in global sales. The announcement follows similar dupilumab biosimilar developments from Alvotech and Advanz in May 2025 and Formycon AG in November 2025.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]